Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
search
Subscribe
FREE
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
Subscribe
FREE
Pharma News, Views & Analysis
Filter
News
Articles
Podcasts
Infographics
Advertise With Us
Advertise With Us
Robeauté’s microbot brain technology secures $28m
The company’s microbot technology holds huge potential for exploring and delivering treatments to the brain.
Read more
Robeauté’s microbot brain technology secures $28m
The company’s microbot technology holds huge potential for exploring and delivering treatments to the brain.
Major changes to patient information leaflets to hit Europe
The European pharma sector is on the brink of regulatory and operational updates with new papers from pharmaceutical associations
Heart failure drug market to reach $33.7bn by 2032
New analysis from GlobalData spans the growth of the heart failure market across seven major markets including the US, Europe and Japan.
Needle-free vaccine technology wins $3.7m in funding from CEPI
Micron Biomedical, an Atlanta-based life sciences company, has received funding for its technology that could improve vaccine access.
Vertex strikes deal for Orna Therapeutics' LNP technology
The deal is set to help Vertex’s development of next-generation gene editing therapies for sickle cell disease and beta-thalassemia.
WuXi Biologics offloads Irish vaccine plant to Merck for $500m
WuXi Biologics sells its vaccine production facility in Ireland to Merck & Co for $500m in the wake of changing regulation in the US.
Could Eli Lilly take the crown in the obesity market?
According to a recent release from GlobalData, Eli Lilly’s obesity offering could become a potential leader in the market.
Gene therapy from Novartis shows promise for children with SMA
Novartis’ Phase III study has demonstrated significant improvement in motor function in children and young adults with spinal muscular atrophy
Loading posts...
1
2
3
…
20
Next »